The relationship between PARP and cancer revolves around the enzymeâs role in DNA repair. Cancer cells often have high levels of DNA damage and rely heavily on DNA repair mechanisms to survive and proliferate. Inhibiting PARP can prevent the repair of DNA damage, leading to the accumulation of DNA lesions, genomic instability, and ultimately cell death. This is particularly effective in cancer cells with existing defects in other DNA repair pathways, such as those with mutations in the BRCA1 or BRCA2 genes.
